Literature DB >> 12100533

In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae.

Cornelia Lass-Flörl1, M Nagl, E Gunsilius, C Speth, H Ulmer, R Würzner.   

Abstract

The minimum inhibitory concentrations (MICs) of amphotericin B and lipid-based amphotericin B formulations against isolates of Aspergillus spp. were tested using a broth microdilution method. Twelve isolates of Aspergillus fumigatus, eight of Aspergillus flavus, six of Aspergillus niger and seven of Aspergillus terreus were examined. In addition, an assay for hyphae of Aspergillus spp. was performed since the invasive form is manifested by the appearance of hyphal structures. MICs of hyphae against lipid-based amphotericin B formulations were within three dilutions higher than those against conidia for almost all isolates of Aspergillus spp. (P < 0.01). In contrast, the differences in the in vitro efficacies of amphotericin B were the lowest for Aspergillus spp. This study demonstrates the importance of the type of inoculum used to test antifungal susceptibilities of Aspergillus spp. The significance of these results for in vivo outcome needs to be determined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100533     DOI: 10.1046/j.1439-0507.2002.00748.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  8 in total

Review 1.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.

Authors:  Jon A Olson; Ancy George; David Constable; Peter Smith; Richard T Proffitt; Jill P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2010-07-06       Impact factor: 5.191

3.  Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

Authors:  Susanne Perkhofer; Maria Locher; Manuel Cuenca-Estrella; Reinhard Rüchel; Reinhard Würzner; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

4.  Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.

Authors:  Susanne Perkhofer; Daniel Jost; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

5.  In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

Authors:  Alicia Gomez-Lopez; Guillermo Garcia-Effron; Emilia Mellado; Araceli Monzon; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  In Vitro Evaluation of Radiolabeled Amphotericin B for Molecular Imaging of Mold Infections.

Authors:  Sebastian Wurster; Samuel Samnick; Lukas Page; Andrew J Ullmann; Fabian Schadt
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

7.  Variability of germinative potential among pathogenic species of Aspergillus.

Authors:  Ricardo Araujo; Acacio Gonçalves Rodrigues
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

8.  In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Susanne Perkhofer; Veronika Lechner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.